ARCHIVES

$1.5 Million In Direct Costs Is Proposed Core Grant Requirement

This article is from The Cancer Letter archive.

Vol. 17 No. 28 | July 12, 1991

Download PDF Visit The Full Archive

Related Articles

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

June 2, 2006

DeVita Changes Mind On OSP Phase Out Reasons, But Presses for “Internalizing” Coordinating Portfolio

January 1, 1988

FDA Requires Independent Confirmation of Disease Progression in Cooperative Group Trials; Seeks Documentation for Avastin in Breast Cancer.

September 15, 2006

Sharfstein To Leave FDA

January 7, 2011

Calif. Stem Cell Group To Collaborate With Canadians.

June 20, 2008

In Brief: Komen Foundation Awards Honor Gingell, Osborne, Freeman; Tobacco Regulation Urged

October 21, 1994